Pathogenesis of insulin resistance in different endocrinopathies

Czech version

Authors: V. Ďurovcová; M. Kršek; M. Haluzík
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2008; 54(4): 368-376
Category: Review

Overview

Visceral obesity, insulin resistance and increased cardiovascular morbidity and mortality are strongly related. Development of visceral obesity and regulation of body fat distribution in general are influenced by many factors. This article is a summary of current knowledge about pathogenesis of insulin resistance in different endocrinopathies, particularly in the Cushingʼs syndrome and acromegaly, as they are both connected with the pathological conditions mentioned above.

Key words:
insulin signaling pathway – visceral obesity – cortisol – growth hormone

Sources

1. Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1) – a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 255–262.

2. Karlsson HK, Zierath JR. Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochem Biophys 2007; 48: 103-113.

3. Del Rincon JP, Iida K, Gaylinn BD et al. Growth Hormone Regulation of p85 α Expression and Phosphoinositide 3-Kinase Activity in Adipose Tissue. Mechanism for Growth Hormone-Mediated Insulin Resistance. Diabetes 2007; 56: 1638–1646.

4. Dominici FP, Turyn D. Growth Hormone-Induced Alterations in the Insulin-Signaling System. Exp Biol Med 2002; 227: 149–157.

5. Dominici FP, Cifone D, Bartke A et al. Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone-transgenic mice. J Endocrinol 1999; 161: 383–392.

6. Lundgren M, Burén J, Ruge T et al. Glucocorticoids Down-Regulate Glucose Uptake Capacity and Insulin-Signaling Proteins in Omental But Not Subcutaneous Human Adipocytes. J Clin Endocrinol Metab 2004; 89: 2989–2997.

7. Pivonello R, Faggiano A, Lombardi G et al. The metabolic syndrome and cardiovascular risk in Cushingʼs syndrome. Endocrinol Metab Clin North Am 2005; 34: 327–339.

8. Walker BR. Glucocorticoids and Cardiovascular Disease. Eur J Endocrinol 2007; 157: 545–559.

9. Vondra K, Hampl R. Glukokortikoidy a diabetes mellitus. Vnitř Lék 2006; 52(5): 493–497.

10. Watts LM, Machem VP, Leedom TA et al. Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism. Diabetes 2005; 54: 1846–1853.

11. Wang M. The role of glucocorticoid action in the patophysiology of the metabolic syndrome. Nutr Metab 2005; 2: 3–17.

12. Marek J, Hána V, Krsek M. How corticoids, growth hormone and oestrogens influence lipids and atherosclerosis. Vnitř Lék 2007; 53: 386–390.

13. Walker BR, Soderberg S, Lindahl B et al. Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J Intern Med 2000; 247: 198–204.

14. Oltmanns KM, Dodt B, Schulte B et al. Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol 2006; 154: 325–331.

15. Stewart PM. Tissue-specific Cushing’s syndrome, 11b-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003; 149: 163–168.

16. Wake DJ, Walker BR. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 in obesity. Endocrine 2006; 29: 101–108.

17. Stewart PM, Boulton A, Kumar S et al. Cortisol Metabolism in Human Obesity: Impaired Cortisone-Cortisol Conversion in Subjects with Central Adiposity. J Clin Endocrinol Metab 1999; 84: 1022–1027.

18. Van Rossum EFC, Lamberts SWJ. Polymorphisms in the Glucocorticoid Receptor Gene and Their Associations with Metabolic Parameters and Body Composition. Recent Prog Horm Res 2004; 59: 333–357.

19. Lin RCI, Wang XL, Morris BJ Association of Coronary Artery Disease With Glucocorticoid Receptor N363S Variant. Hypertension 2003; 41: 404–407.

20. Rosmond R. The Glucocorticoid Receptor Gene and Its Association to Metabolic Syndrome. Obes Res 2002; 10: 1078–1086.

21. Van Rossum EF, Koper JW, Huizenga NA et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002; 51: 3128–3134.

22. Van Rossum EFC, Feelders RA, Van den Beld AW et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with better survival and low C-reactive protein levels in elderly men. Am J Med 2004; 117: 158–162.

23. Van Rossum EFC, De Jong FJ, Den Heijer T et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene protects against white matter lesions and dementia, 82. In: Program & Abstracts of the 85th Annual Meeting of the Endocrine Society, Philadelphia 2003.

24. Van Rossum EFC, Voorhoeve PG, Te Velde SJ et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J Clin Endocrinol Metab 2004; 89: 4004–4009.

25. Fernandez-Real JM, Puget M, Grasa M et al. Serum Corticosteroid-Binding Globulin Concentration and Insulin Resistance Syndrome: A Population Study. J Clin Endocrinol Metab 2002; 87: 4686-4690.

26. Fernandez-Real JM, Pugeat M, López-Bermejo A et al. Corticosteroid-binding globulin affects the relationship between circulating adiponectin and cortisol in men and women. Metabolism 2005; 54: 584–589.

27. Pasarica M, Zachwieja JJ, Dejonge L et al. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab 2007; 92: 4265–4270.

28. Ahmad AM, Hopkins MT, Thomas J et al. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol 2001; 54: 709–717.

29. Vilar L, Naves LA, Costa SS et al. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 2007; 13: 363–372.

30. Wajchenberg BL. Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome. Endocr Rev 2000; 21: 697–738.

31. Franco C, Brandberg J, Lönn L et al. Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: A 12-Month Placebo-Controlled Trial. J Clin Endocrinol Metab 2004; 90: 1466–1474.

32. Ridderstrale M. Signaling Mechanism for the Insulin-like Effects of Growth Hormone – Another Example of a Classical Hormonal Negative Feedback Loop. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 79–92.

33. Gaur S, Schwartz Y, Tai LR et al. Insulin Produces a Growth Hormone-Like Increase in Intracellular Free Calcium Concentration in Okadaic Acid-Treated Adipocytes. Endocrinology 1998; 139: 4953–4961.

34. Piwien-Pilipuk G, Huo JS, Schwartz J. Growth hormone signal transduction. J Pediatr Endocrinol Metab 2002; 15: 771–786.

35. Ridderstråle M, Amstrup J, Hilton DJ et al. SOCS-3 is involved in the downregulation of the acute insulin-like effects of growth hormone in rat adipocytes by inhibition of Jak2/IRS-1 signaling. Horm Metab Res 2003; 35: 169–177.

36. Barbour LA, Rahman SM, Gurevich I et al. Increased P85-αIs a Potent Negative Regulator of Skeletal Muscle Insulin Signaling and Induces in Vivo Insulin Resistance Associated with Growth Hormone Excess. J Biol Chem 2005; 280: 37489–37494.

37. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling R1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24: 5434–5446.

38. Fasshauer M, Kralisch S, Klier M et al. Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor – and Jak/Stat-signaling pathways in 3T3-L1 adipocytes. J Endocrinol 2004; 181: 129–138.

39. Dominici FP, Argentino DP, Munoz MC et al. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 2005; 15: 324–336.

40. Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab 2004; 89: 2548–2556.